| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02628080 | Carcinoma, Non-Small-Cell Lung | Drug: Atovaquone | University of Oxford | Early Phase 1 | 2016-05-01 | 2016-06-21 |
| NCT01858831 | Malaria | Drug: Atovaquone/proguanil HCL|Drug: Atovaquone | GlaxoSmithKline | Phase 1 | 2012-04-01 | 2017-03-21 |
| NCT02297477 | Malaria | Drug: atovaquone-proguanil|Drug: artesunate-atovaquone-proguanil | Armed Forces Research Institute of Medical Sciences, Thailand|National Centre for Parasitology, Entomology and Malaria Control, Cambodia|Naval Medical Research Center, Asia (NMRC-A) | Phase 4 | 2014-12-01 | 2016-01-10 |
| NCT00000773 | Pneumonia, Pneumocystis Carinii|HIV Infections | Drug: Atovaquone | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | null | 2012-03-30 |
| NCT00984256 | Malaria | Drug: Atovaquone Proguanil|Other: Procedure - malaria challenge | U.S. Army Medical Research and Materiel Command | Phase 2 | 2009-09-01 | 2013-10-29 |
| NCT00421473 | HIV Infections|Malaria | Drug: Atovaquone / Proguanil | Radboud University | Phase 4 | 2007-03-01 | 2009-02-24 |
| NCT00002340 | Pneumonia, Pneumocystis Carinii|HIV Infections | Drug: Atovaquone|Drug: Pentamidine isethionate | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 3 | null | 2005-06-23 |
| NCT01479361 | HIV|PCP|Toxoplasmosis | Drug: Atovaquone 750 mg twice daily|Drug: Atovaquone 1500 mg twice daily | National Institutes of Health Clinical Center (CC) | Phase 1 | 2011-10-31 | 2017-01-24 |
| NCT00000802 | Pneumonia, Pneumocystis Carinii|HIV Infections | Drug: Atovaquone|Drug: Dapsone | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | null | 2012-04-02 |
| NCT00001991 | Pneumonia, Pneumocystis Carinii|HIV Infections | Drug: Atovaquone | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | | null | 2005-06-23 |
| NCT00084227 | Malaria, Falciparum | Drug: Azithromycin/Chloroquine|Drug: Atovaquone/Proguanil | Pfizer | Phase 2|Phase 3 | 2004-07-01 | 2011-05-10 |
| NCT00001994 | Toxoplasmosis, Cerebral|HIV Infections | Drug: Atovaquone | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | | null | 2005-06-23 |
| NCT00001990 | Pneumonia, Pneumocystis Carinii|HIV Infections | Drug: Atovaquone | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | | null | 2005-06-23 |
| NCT00001996 | Pneumonia, Pneumocystis Carinii|HIV Infections | Drug: Atovaquone|Drug: Pentamidine isethionate | Glaxo Wellcome|NIH AIDS Clinical Trials Information Service | Phase 2 | null | 2005-06-23 |
| NCT00000794 | Toxoplasmosis, Cerebral|HIV Infections | Drug: Sulfadiazine|Drug: Clarithromycin|Drug: Atovaquone|Drug: Pyrimethamine|Drug: Leucovorin calcium | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | null | 2012-04-02 |
| NCT00000655 | Pneumonia, Pneumocystis Carinii|HIV Infections | Drug: Atovaquone|Drug: Sulfamethoxazole-Trimethoprim | National Institute of Allergy and Infectious Diseases (NIAID)|Glaxo Wellcome | Phase 2 | null | 2011-02-25 |
| NCT00379821 | Plasmodium Falciparum Infection | Drug: Atovaquone-proguanil|Drug: Artesunate|Drug: Azithromycin|Drug: Chloroquine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2007-02-01 | 2014-08-07 |
| NCT00000811 | Bacterial Infections|Pneumonia, Pneumocystis Carinii|HIV Infections | Drug: Azithromycin|Drug: Atovaquone|Drug: Sulfamethoxazole-Trimethoprim | National Institute of Allergy and Infectious Diseases (NIAID)|Pfizer|Glaxo Wellcome|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 | null | 2012-04-02 |
| NCT00444106 | Malaria|Falciparum | Drug: Artesunate-mefloquine|Drug: Atovaquone-proguanil|Drug: Artemether-lumefantrine | Novartis | Phase 4 | 2007-05-01 | 2011-04-01 |
| NCT02858817 | Malaria | Drug: atovaquone/proguanil 250mg/100mg (A/P)|Biological: PfSPZ Challenge (NF54)|Other: NaCl 0,9% | University Hospital Tuebingen|Sanaria Inc. | Phase 1 | 2016-10-01 | 2016-08-05 |
| NCT01442168 | Malaria, Falciparum | Drug: Sevuparin sodium + atovaquone/proquanil|Drug: atovaquone/proquanil | Dilaforette AB|University of Oxford | Phase 1|Phase 2 | 2011-09-01 | 2014-08-18 |
| NCT00386750 | Malaria|Falciparum | Drug: Artemether-lumefantrine | Novartis Pharmaceuticals|Novartis | Phase 4 | 2005-06-01 | 2012-04-25 |
